Sirolimus- vs. paclitaxel-eluting stents for the treatment of unprotected left main coronary artery stenosis: Complete 2-year follow-up of a two-center registry
Introduction
With the introduction of drug-eluting stents (DES) which was shown to decrease repeat revascularization [1], percutaneous coronary intervention (PCI) has become a possible treatment option for complex and high-risk lesions including unprotected left main coronary artery (LMCA) stenosis. Rising amount of data has shown the feasibility of PCI and its comparability with bypass surgery in patients with unprotected LMCA stenosis [2], [3], [4], [5], [6], [7]. As PCI is performed more widely in patients with LMCA stenosis, the use of optimal procedure techniques and selection of proper stent types deserve attention. Although there have been robust data comparing the performance of sirolimus-(SES) vs. paclitaxel-eluting stents (PES), there is still limited data comparing these 1st generation DESs in unprotected LMCA stenosis. In the present study, we compared 2-year clinical outcome of SES and PES using a two-center left main registry from the Seoul National University Main and Bundang Hospital.
Section snippets
Patients
The analysis was from a two-center DES registry of consecutive patients with LMCA or LMCA equivalent disease treated at Seoul National University Main and Bundang Hospital. We analyzed all patients with unprotected LMCA treated by PCI using first generation DES from March 2003 and June 2007. Unprotected LMCA disease was defined as more than 50% LMCA stenosis, and left main equivalent disease as severe stenosis (≥ 70%) of both left anterior descending (LAD) and left circumflex (LCx) coronary
Baseline characteristics
We identified 196 patients (SES: 141 patients, PES: 55 patients) with unprotected LMCA stenosis who received PCI during the study period. The baseline clinical characteristics of the patients are listed in Table 1. The mean age of the patients was 64.2 ± 11.7 years, 69% were males, and 38% were diabetic. Reflecting the feature of ‘all-comer’ analysis, 38% of the patients had presented with stable angina, while 57% with acute coronary syndrome. While hypertension was more frequent in the PES group,
Discussion
Since the introduction of DES into the commercial market, there have been many comparisons of the first generation SES (Cypher®) and PES (Taxus™) stents in different studies such as the ISAR-DESIRE, REALITY, SORT OUT II, SIRTAX trial [11], [12], [13], [14], [15]. However, there is still paucity of data comparing the two types of stent in unprotected LMCA stenosis. In this study, we compared the outcome of SES vs. PES in unprotected LMCA stenosis. In this analysis, we found that PCI (using SES
Conclusion
In patients with LMCAS, DES implantation was both feasible and safe. Furthermore, PES and SES showed comparable long-term clinical outcomes regarding hard endpoints and MACE.
Acknowledgements
This study was supported by a grant from the Clinical Research Center for Ischemic Heart Disease, Seoul, Republic of Korea (0412-CR02-0704-0001) and a grant from the Innovative Research Institute for Cell Therapy, Seoul National University Hospital (A062260), sponsored by the Ministry of Health, Welfare & Family, Republic of Korea. The authors of this manuscript have certified that they comply with the Principles of Ethical Publishing in the International Journal of Cardiology [25].
References (25)
- et al.
Longest available clinical outcomes after drug-eluting stent implantation for unprotected left main coronary artery disease: the delft (drug eluting stent for left main) registry
J Am Coll Cardiol
(2008) - et al.
Sirolimus-eluting versus paclitaxel-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: a combined research and t-search long-term analysis
J Am Coll Cardiol
(2006) - et al.
A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease
J Am Coll Cardiol
(2007) - et al.
Coronary artery bypass grafting versus drug-eluting stent implantation for left main coronary artery disease (from a two-center registry)
Am J Cardiol
(2010) - et al.
Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease
J Am Coll Cardiol
(2009) - et al.
Impact of drug-eluting stent selection on long-term clinical outcomes in patients treated for unprotected left main coronary artery disease: the sirolimus vs paclitaxel drug-eluting stent for left main registry (sp-delft)
Int J Cardiol
(2009) - et al.
Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the main-compare (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry
J Am Coll Cardiol
(2009) - et al.
Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the sirtax trial
J Am Coll Cardiol
(2007) - et al.
Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up
Am J Cardiol
(2006) Ethical authorship and publishing
Int J Cardiol
(2009)
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents
N Engl J Med
Stents versus coronary-artery bypass grafting for left main coronary artery disease
N Engl J Med
Cited by (8)
Dual Antiplatelet Therapy Duration Determines Outcome After 2- But Not 1-Stent Strategy in Left Main Bifurcation Percutaneous Coronary Intervention
2018, JACC: Cardiovascular InterventionsEverolimus-versus sirolimus-eluting stents for the treatment of unprotected left main coronary artery stenosis (results from the EXCELLENT registry)
2013, International Journal of CardiologyCitation Excerpt :In contemporary real world PCI for ULMCA stenosis, DES is preferred to bare metal stents because of lowered risk of restenosis and repeat revascularization, and similar or favorable outcomes in terms of death, MI, and stent thrombosis when compared with bare stents [14,15]. There have been several comparisons between the two first generation DESs (PES and SES) in this lesion subset, which showed similar clinical outcomes [16–18]. However, data comparing the outcomes between second-generation DES with first-generation DES are very limited.
Response to "sirolimus or paclitaxel drug eluting stent in left main disease: The winner is..."
2012, International Journal of CardiologySirolimus or paclitaxel drug eluting stent in left main disease: The winner is⋯
2011, International Journal of CardiologyComparing the clinical outcomes of single vs. systematic dual stenting strategies for unprotected left main bifurcation lesion: a systematic review and meta-analysis
2023, Frontiers in Cardiovascular MedicineLong-term efficacy and safety of domestic drug-eluting stents in patients with acute coronary syndrom
2015, Chinese Journal of Emergency Medicine
- 1
The first two authors contributed equally to the study.